A Vancouver-based research team led by Canada’s most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enough, a daily regimen of the non-prescription NSAID (nonsteroidal anti-inflammatory drug) ibuprofen can prevent the onset of Alzheimer’s disease.
This means that by taking an over-the-counter medication, people can ward off a disease that, according to Alzheimer’s Disease International’s World Alzheimer Report 2016, affects an estimated 47 million people worldwide, costs health care systems worldwide more than US$818 billion  per year and is the fifth leading cause of death in those aged 65 or older.
The Alzheimer’s Association estimates that there are more than 5 million cases in the United States alone, with a new case being identified every 66 seconds. The annual cost to the country in 2017 is estimated have been US$259 billion, with that figure predicted to potentially rise to US$1.1 trillion  by 2050.
Dr. McGeer, who is President and CEO of Vancouver-based Aurin Biotech, and his wife, Dr. Edith McGeer, are among the most cited neuroscientists in the world. Their laboratory is world-renowned for their 30 years of work in neuroinflammation and neurodegenerative diseases, particularly Alzheimer’s disease. A paper detailing Dr. McGeer’s most recent discoveries has been published in the prestigious Journal of Alzheimer’s Disease.
In 2016, Dr. McGeer and his team announced that they had developed a simple saliva test that can diagnose Alzheimer’s disease, as well as predict its future onset. The test is based on measuring the concentration of the peptide amyloid-beta protein 42 (Abeta 42) secreted in saliva. In most individuals, the rate of Abeta 42 production is almost exactly the same regardless of sex or age. However, if that rate of production is two to three times higher, those individuals are destined to develop Alzheimer’s disease. That is because Abeta 42 is a relatively insoluble material, and although it is made everywhere in the body, deposits of it occur only in the brain, causing neuroinflammation, which destroys neurons in the brains of people with Alzheimer’s disease.
Contrary to the widely held belief that Abeta 42 is made only in the brain, Dr. McGeer’s team demonstrated that the peptide is made in all organs of the body and is secreted in saliva from the submandibular gland. As a result, with as little as one teaspoon of saliva, it is possible to predict whether an individual is destined to develop Alzheimer’s disease. This gives them an opportunity to begin taking early preventive measures such as consuming non-prescription non-steroidal drugs (NSAIDs) such as ibuprofen.
“What we’ve learned through our research is that people who are at risk of developing Alzheimer’s exhibit the same elevated Abeta 42 levels as people who already have it; moreover, they exhibit those elevated levels throughout their lifetime so, theoretically, they could get tested anytime,” says Dr. McGeer. “Knowing that the prevalence of clinical Alzheimer’s Disease commences at age 65, we recommend that people get tested ten years before, at age 55, when the onset of Alzheimer’s would typically begin. If they exhibit elevated Abeta 42 levels then, that is the time to begin taking daily ibuprofen to ward off the disease.
“Unfortunately, most clinical trials to date have focused on patients whose cognitive deficits are already mild to severe, and when the therapeutic opportunities in this late stage of the disease are minimal. Consequently, every therapeutic trial has failed to arrest the disease’s progression. Our discovery is a game changer. We now have a simple test that can indicate if a person is fated to develop Alzheimer’s disease long before it begins to develop. Individuals can prevent that from happening through a simple solution that requires no prescription or visit to a doctor. This is a true breakthrough since it points in a direction where AD can eventually be eliminated.”
The Latest on: Alzheimer’s disease
via Google News
The Latest on: Alzheimer’s disease
- Could Getting a Vaccine Lower Your Alzheimer’s Risk?on July 7, 2021 at 7:18 am
Two new studies find that getting a flu shot and the pneumonia vaccine may also lower people’s risk of Alzheimer’s disease. In one study, people who were vaccinated against pneumonia between the ages ...
- Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer’s Diseaseon July 7, 2021 at 7:03 am
(Nasdaq: SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that a new patent has been awarded by the U.S. Patent and ...
- A New Alzheimer’s Drug Offers More Questions Than Answerson July 7, 2021 at 6:44 am
The approval of Aduhelm to treat Alzheimer’s disease has raised hope among older adults, but many doctors wonder if it is warranted.
- The #1 Cause of Alzheimer's, According to Expertson July 7, 2021 at 6:30 am
Alzheimer's disease is a well-known, and much-feared, disorder of the later years: More than five million Americans are currently affected. But it's still poorly understood. Scientists are still ...
- SciSparc to Commence Phase IIa Clinical Trial of SCI-110 for the Treatment of Alzheimer's Disease and Agitationon July 7, 2021 at 5:00 am
SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (OTCQB: SPRCY) a specialty, clinical-stage pharmaceutical company focusing on ...
- Could a longer reproductive period put women at greater risk for Alzheimer disease?on July 7, 2021 at 12:02 am
Estrogen has been thought to play a role in a woman's risk of developing Alzheimer disease (AD). A new study has taken a different approach to identifying risk factors for AD by examining the ...
- In search of how memory fails, UT Alzheimer's disease study provides rare insight, thanks to ratson July 6, 2021 at 11:10 am
A University of Texas study published last month revealed for the first time what happens when the brain makes a memory mistake.
- Linus Health raises $55M for early screening for Alzheimer’s diseaseon July 6, 2021 at 10:30 am
Linus Health has raised $55 million in funding for screening tools to diagnose dementia and Alzheimer's disease.
- Athira Pharma Starts Open-Label Extension Of Alzheimer's Disease Trialson July 6, 2021 at 6:17 am
Athira Pharma Inc (NASDAQ: ATHA ) has started enrollment in an open-label extension (OLEX) study for its ongoing Phase 2/3 LIFT-AD and Phase 2 ACT-AD studies of ATH-1017 for the treatment of ...
via Bing News